Applied Genetic Tech (AGTC) 14.82 $AGTC AGTC and the

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Applied Genetic Tech (AGTC) 14.82 $AGTC

AGTC and the Medical College of Wisconsin Announce Publication of Natural History Study Data Evaluating Residual Photoreceptor Cone Status in Patients with CNGB3-associated Achromatopsia
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and the Medical College of Wisconsin (MCW) today announced the publication of data from studies evaluating the density of cone photoreceptors in patients with CNGB3-associated achromatopsia (ACHM). The peer-reviewed study results appear in the current issue of Investigative Ophthalmology and Visual Science.
AGTC: 14.82 (-0.43)

AGTC to Host Research Day on June 21, 2016 in New York
GlobeNewswire - Thu Jun 09, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will host a Research Day in New York City on June 21, 2016. AGTC management will be joined by two of its scientific collaborators to discuss the range of ophthalmology clinical endpoints, how they are measured, how they define and describe the vision experienced by the patient, and how results in AGTC's clinical development programs could be reported.
AGTC: 14.82 (-0.43)

AGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the European Commission (EC) has granted an orphan medicinal product designation to its investigational gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
AGTC: 14.82 (-0.43)

Applied Genetic Technologies posts 3Q profit
Automated Insights - Mon May 09, 4:25PM CDT
ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Monday reported fiscal third-quarter net income of $2 million, after reporting a loss in the same period a year earlier.
AGTC: 14.82 (-0.43)

AGTC Announces Financial Results for the Quarter Ended March 31, 2016
GlobeNewswire - Mon May 09, 3:03PM CDT
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended March 31, 2016. The company also announced that it plans to expand its AAV technology platform to address targets that could help treat patients with inherited hearing disorders.
AGTC: 14.82 (-0.43)

Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years
GlobeNewswire - Thu May 05, 6:00AM CDT
Researchers from the University of Massachusetts Medical School today announced new data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for alpha-1 antitrypsin (AAT) deficiency, an inherited genetic defect that results in severe loss of lung function. The investigational gene therapy was developed by Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of gene therapies for the treatment of rare diseases. Study results were presented in a podium session at the American Society of Gene and Cell Therapy (ASGCT) 19 Annual Meeting, taking place from May 4 - 7.
AGTC: 14.82 (-0.43)

Novel Investigational Gene-Based Therapy for X-Linked Retinitis Pigmentosa Demonstrates Functional Rescue of Photoreceptor Structure and Function in Canine Model
GlobeNewswire - Mon May 02, 6:00AM CDT
Researchers from the University of Pennsylvania today announced new animal study data evaluating the efficacy of an investigational adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease that causes progressive vision loss in boys and young men. The investigational gene therapy was developed by Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of gene therapies for the treatment of rare diseases. Study results were presented in a poster session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 1 - 5.
AGTC: 14.82 (-0.43)

AGTC Announces Participation & Presentations at Upcoming Scientific & Investor Conferences
GlobeNewswire - Fri Apr 29, 6:07AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the company and its collaborators will participate in in the following upcoming conferences.
AGTC: 14.82 (-0.43)

AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 9, 2016
GlobeNewswire - Thu Apr 28, 6:05AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the quarter ended March 31, 2016 after the market closes on Monday, May 9, 2016. AGTC management will host a conference call beginning at 5:00 pm Eastern Time that day to review results and provide a corporate update.
AGTC: 14.82 (-0.43)

AGTC Announces Data Evaluating Novel AAV-Based Gene Therapy as a Potential Treatment for Leber Congenital Amaurosis (LCA) and Severe Early-Childhood-Onset Retinal Degeneration (SECORD)
GlobeNewswire - Fri Apr 22, 6:01AM CDT
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating an experimental recombinant AAV vector gene delivery in patients with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD), two related retinal diseases caused by mutations in the RPE65 gene that cause severe loss of vision in infancy. Results from the study, entitled "Results at 2 Years after Gene Therapy for RPE65-deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy," were published online in the peer-reviewed journal Ophthalmology and will appear in the April print issue of the journal.
AGTC: 14.82 (-0.43)

American Gilsonite Announces Retirement of Chief Accounting Officer Doug Maughan
PR Newswire - Thu Apr 21, 4:16PM CDT
American Gilsonite Company, Inc. ("American Gilsonite" or "AGC", the world's major supplier of Gilsonite®, today announced the retirement of Chief Accounting Officer, Doug Maughan, effective April 15, 2016. From 2008 to 2015, Maughan served as Chief Financial Officer of American Gilsonite. In November 2015, he announced his anticipated retirement and, since that time, stayed on as the Chief Accounting Officer of the Company.
AGTC: 14.82 (-0.43)

AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia
GlobeNewswire - Wed Apr 20, 6:01AM CDT
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the publication of two studies that provide support for the Company's planned clinical investigation of its novel investigational gene therapy candidate for treating achromatopsia caused by mutations in the CNGB3 gene. Results, evaluating toxicology and biodistribution profiles in mouse and non-human primate models, were published online in the peer-reviewed journal Human Gene Therapy Clinical Development and appear in the March print issue.
AGTC: 14.82 (-0.43)

New Strong Buy Stocks for April 11th
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 9:04AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
AGTC: 14.82 (-0.43), AYI: 258.89 (-3.20), AMBR: 8.81 (unch), BANC: 21.53 (-0.28), APRI: 0.30 (-0.02)

Surging Earnings Estimates Signal Good News for Applied Genetic Technologies (AGTC)
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 7:31AM CDT
Positive earnings estimate revisions, coupled with impressive Zacks Rank has made Applied Genetic Technologies (AGTC) an interesting choice for the investors.
AGTC: 14.82 (-0.43)

American Gilsonite to Announce 4th Quarter and Full Year 2015 Financial Results
PR Newswire - Fri Mar 11, 4:44PM CST
American Gilsonite Company, Inc. ("American Gilsonite", or "AGC", the world's major supplier of Gilsonite®, announced that it will post financial and operating results for the fourth quarter and full year ended December 31, 2015 to the Company's Intralinks investor site on Wednesday, March 23, 2016.
AGTC: 14.82 (-0.43)

AGTC to Participate in Upcoming Investor and Scientific Conferences
GlobeNewswire - Mon Mar 07, 3:01PM CST
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that company management will participate in four upcoming investor and scientific conferences.
AGTC: 14.82 (-0.43)

Seattle Genetics' (SGEN) Q4 Loss Wider than Expected
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 1:54PM CST
Seattle Genetics' (SGEN) 4Q revenues surpassed expectations with Adcetris sales shooting up 35.5%.
AGTC: 14.82 (-0.43), SGEN: 48.40 (-0.82), ANIK: 49.41 (-1.23)

New Strong Buy Stocks for February 9th
Zacks Equity Research - Zacks Investment Research - Tue Feb 09, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AGTC: 14.82 (-0.43), ACHC: 51.40 (-1.19), ACAS: 16.46 (-0.04), AFAM: 39.57 (-0.48), ADSK: 58.20 (-1.54)

AGTC Announces Financial Results for the Quarter Ended December 31, 2015
GlobeNewswire - Mon Feb 08, 3:01PM CST
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, with a primary focus on ophthalmology, today announced financial results for the quarter ended December 31, 2015. The company also announced that Biogen (NASDAQ:BIIB) has selected adrenoleukodystrophy (ALD) as the first publicly announced of the three discovery programs under its collaboration with AGTC.
AGTC: 14.82 (-0.43), BIIB: 298.60 (-3.23)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 34

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
NestWorks' C500: Shaking Up CNC at Formnext 2026

Updated Category News Views 86

NestWorks C500: A Game Changer for Makers Folks, gather 'round, because NestWorks is turning heads with their C500 desktop CNC machine. As it lands firmly on TIME’s Best Inventions of 2026 list, this ain't just another gadget adorning a workshop—all eyes are on it at Formnext 2026. From November 17–20, Frankfurt is the stage where NestWorks plans to showcase how...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 16

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 427

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 372

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 42

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 55

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading

Top 5 Most Recently Viewed Articles

Insigneo Welcomes Esteban Diaz to Enhance Wealth Management

Updated Category News Views 159

Insigneo Strengthens Its Wealth Management Team Insigneo, a prominent name in wealth management, proudly announces the addition of Esteban Diaz as Senior Vice President. This significant recruitment is part of the firm’s ongoing commitment to enhancing its network, particularly in serving high-net-worth clients in the Latin American region. About Esteban Diaz's...

Continue Reading
Exploring RBC Bearings: A Five-Year Investment Journey

Updated Category News Views 172

RBC Bearings: A Strong Investment Over Time RBC Bearings has proven to be a formidable player in the market, showcasing impressive performance over the last five years. With an average annual return of 18.74%, any investment made during this period would have reaped considerable rewards. The Growth of a $1000 Investment Imagine if you had decided to invest $1000 in RBC...

Continue Reading
ANI Pharmaceuticals Enhances Ophthalmology Strategy with Experts

Updated Category News Views 227

ANI Pharmaceuticals Launches FutureVision Advisory Council In a strategic move to bolster its ophthalmology and retina franchise, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has established the FutureVision Advisory Council. This dedicated council aims to guide the ongoing innovations within ANI's Rare Disease portfolio, focusing particularly on ophthalmological care....

Continue Reading
Unlocking Financial Freedom: The CESUR Mining Game Changer

Updated Category News Views 99

Understanding CESUR Mining and Its Impact CESUR Mining is quickly becoming a significant player in the world of cryptocurrency. This innovative platform enables users to tap into the potential of cloud mining, allowing them to earn passive income without the need for technical knowledge or constant monitoring. Established with the vision to simplify the mining process,...

Continue Reading
Understanding Nvidia's Role in the S&P 500 Market Dynamics

Updated Category News Views 204

Nvidia's Influence on the S&P 500 Market The stock market can be quite a wild ride, with swings that can astonish even the most experienced investors. Recently, stocks started off relatively flat but soon encountered volatility, leading to a significant rally largely fueled by news surrounding Nvidia. This surge prompts important questions about how the S&P 500 will...

Continue Reading